^
Association details:
Biomarker:Chr t(11;14)
Cancer:Multiple Myeloma
Drug:filanesib (ARRY-520) (KIF11 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

Published date:
12/17/2021
Excerpt:
The combination of filanesib, bortezomib, and dexamethasone continues to show safety and encouraging activity in relapsed/refractory multiple myeloma, particularly in those patients with 1q21 gain and t(11;14).
Secondary therapy:
bortezomib
DOI:
10.1002/cam4.4451